John M. Leonard
Known title: President and CEOCIK: 0001563584
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IQVIA Expands Veeva Partnership and Raises Price Targets. IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.
Transaction History
| NTLA | ▼ Sell | Open Market | 2,785 | $36K | 8/21/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 19,890 | $251K | 8/20/2026 | View on chart |
| IQV | ▲ Buy | Grant | 1,571 | $0 | 4/23/2026 | View on chart |
| NTLA | ▲ Buy | Grant | 156,400 | $0 | 3/1/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 34,146 | $314K | 1/5/2026 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 8,557 | $58K | 12/12/2025 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 49,959 | $341K | 12/11/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 49,959 | $474K | 12/11/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 32,832 | $311K | 12/11/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 5,355 | $51K | 12/11/2025 | View on chart |
| IQV | ▲ Buy | Grant | 1,592 | $0 | 4/24/2025 | View on chart |
| NTLA | ▲ Buy | Grant | 136,000 | $0 | 3/1/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 26,807 | $327K | 1/3/2025 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 7,850 | — | 1/1/2025 | View on chart |
| IQV | ▲ Buy | Grant | 1,047 | $0 | 5/7/2024 | View on chart |
| NTLA | ▲ Buy | Grant | 113,586 | $0 | 3/1/2024 | View on chart |
| NTLA | ▼ Sell | Open Market | 19,223 | $566K | 1/3/2024 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 7,848 | — | 1/1/2024 | View on chart |
| IQV | ▲ Buy | Grant | 1,063 | $0 | 5/10/2023 | View on chart |
| NTLA | ▲ Buy | Grant | 91,036 | $0 | 3/1/2023 | View on chart |
| NTLA | ▼ Sell | Open Market | 6,673 | $248K | 1/4/2023 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 7,848 | — | 1/1/2023 | View on chart |
| IQV | ▲ Buy | Grant | 995 | $0 | 5/11/2022 | View on chart |
| NTLA | ▲ Buy | Grant | 40,990 | $0 | 3/1/2022 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 7,848 | — | 1/1/2022 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,493 | $280K | 1/1/2022 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 28,750 | $674K | 9/1/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 15,985 | $293K | 9/1/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 44,735 | $7.6M | 9/1/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 37,833 | $552K | 8/31/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 37,833 | $5.9M | 8/31/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 11,637 | $156K | 8/30/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 27,167 | $396K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,055 | $314K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,334 | $359K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 7,428 | $1.2M | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 15,567 | $2.4M | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 4,758 | $747K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 3,123 | $493K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,598 | $414K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 725 | $116K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 216 | $35K | 8/30/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 27,139 | $364K | 8/23/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 18,874 | $2.9M | 8/23/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 8,165 | $1.2M | 8/23/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 100 | $15K | 8/23/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 5,963 | $908K | 8/19/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 22,682 | $304K | 8/19/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 9,726 | $1.5M | 8/19/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 6,993 | $1.1M | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer
Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.